OncRef

Clinical Trial: NCT02290951

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:Regeneron Pharmaceuticals
Information Provided By:Regeneron Pharmaceuticals
Last Update Posted:2025-10-10

Study Overview

Brief Summary

This study has two parts with distinct study objectives and study design. In part A, odronextamab is studied as an intravenous (IV) administration with a dose escalation and a dose expansion phase for B-NHL and CLL. The dose escalation phase for B-NHL and the CLL study are closed at the time of protocol amendment 17. In part B, odronextamab is studied as a subcutaneous (SC) administration with a dose finding and a dose expansion phase for B-NHL.

Official Title

An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy (ELM-1)

Conditions

Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia

Intervention / Treatment

  • Drug: Odronextamab multiple dose levels
  • Drug: Odronextamab multiple dose levels

Other Study ID Numbers

  • R1979-HM-1333
  • 2015-004491-30
  • 2024-514938-20-00
  • 2015

Start Date (Actual)

2015-01-09

Primary Completion Date (Actual)

2025-08-21

Study Completion Date (Actual)

2025-08-21

Enrollment (Actual)

200

Study Type

Interventional

Phase

Phase 1